These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
336 related items for PubMed ID: 18618720
1. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Nga ME, Lim GS, Soh CH, Kumarasinghe MP. Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720 [Abstract] [Full Text] [Related]
2. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X, Zhu X. J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217 [Abstract] [Full Text] [Related]
3. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma. Coli A, Bigotti G, Parente P, Federico F, Castri F, Massi G. J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102 [Abstract] [Full Text] [Related]
4. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Sack MJ, Astengo-Osuna C, Lin BT, Battifora H, LiVolsi VA. Mod Pathol; 1997 Jul; 10(7):668-74. PubMed ID: 9237176 [Abstract] [Full Text] [Related]
5. Immunohistochemical diagnosis of papillary thyroid carcinoma. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350 [Abstract] [Full Text] [Related]
6. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions. Palo S, Biligi DS. Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206 [Abstract] [Full Text] [Related]
8. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Rossi ED, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G. Histopathology; 2006 Jun 25; 48(7):795-800. PubMed ID: 16722927 [Abstract] [Full Text] [Related]
9. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions. Mataraci EA, Ozgüven BY, Kabukçuoglu F. Pol J Pathol; 2012 Mar 25; 63(1):58-64. PubMed ID: 22535608 [Abstract] [Full Text] [Related]
10. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Abd-El Raouf SM, Ibrahim TR. Pathol Res Pract; 2014 Dec 25; 210(12):971-8. PubMed ID: 25041837 [Abstract] [Full Text] [Related]
11. The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma. Chandan VS, Faquin WC, Wilbur DC, Khurana KK. Cancer; 2006 Oct 25; 108(5):331-6. PubMed ID: 16944537 [Abstract] [Full Text] [Related]
12. Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility. Schmitt AC, Cohen C, Siddiqui MT. Cancer Cytopathol; 2010 Aug 25; 118(4):196-202. PubMed ID: 20731005 [Abstract] [Full Text] [Related]
13. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules. Han RL, Wang J, Zhang FJ, Zhao N, Gao BL. Pathol Oncol Res; 2019 Jul 25; 25(3):1075-1081. PubMed ID: 30361909 [Abstract] [Full Text] [Related]
14. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions]. Tong J, Wang Y, Da JP. Zhonghua Zhong Liu Za Zhi; 2011 Aug 25; 33(8):599-604. PubMed ID: 22325220 [Abstract] [Full Text] [Related]
15. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. Ceyran AB, Şenol S, Şimşek BÇ, Sağıroğlu J, Aydın A. Int J Clin Exp Pathol; 2015 Aug 25; 8(4):3670-80. PubMed ID: 26097548 [Abstract] [Full Text] [Related]
16. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules. Cui W, Sang W, Zheng S, Ma Y, Liu X, Zhang W. Clin Lab; 2012 Aug 25; 58(7-8):673-80. PubMed ID: 22997967 [Abstract] [Full Text] [Related]
17. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Abouhashem NS, Talaat SM. Pathol Res Pract; 2017 May 25; 213(5):509-517. PubMed ID: 28214214 [Abstract] [Full Text] [Related]
18. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Sahoo S, Hoda SA, Rosai J, DeLellis RA. Am J Clin Pathol; 2001 Nov 25; 116(5):696-702. PubMed ID: 11710686 [Abstract] [Full Text] [Related]
19. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis. Ma H, Yan J, Zhang C, Qin S, Qin L, Liu L, Wang X, Li N. Int J Clin Exp Pathol; 2014 Nov 25; 7(11):7999-8007. PubMed ID: 25550843 [Abstract] [Full Text] [Related]
20. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A. Anticancer Res; 2005 Nov 25; 25(1A):179-82. PubMed ID: 15816536 [Abstract] [Full Text] [Related] Page: [Next] [New Search]